Barclays Has Lowered Expectations for DaVita (NYSE:DVA) Stock Price

Key Points

• Barclays lowered DaVita’s price target from $224 to $216 while maintaining an “equal weight” rating, implying 16.52% upside from the stock’s reported $185.37 price.
• Analyst sentiment remains broadly positive: DaVita has four Buy and three Hold ratings, an overall “Moderate Buy” consensus, and an average price target of $235.86.
• DaVita exceeded quarterly expectations, reporting $3.82 in EPS versus the $3.57 consensus and $3.58 billion in revenue; institutional investors own 90.12% of the company, including a major new position from Berkshire Hathaway.

DaVita (NYSE:DVA - Get Free Report) had its price target reduced by Barclays from $224.00 to $216.00 in a report released on Monday, Benzinga reports. The brokerage currently has an "equal weight" rating on the stock. Barclays's price objective would indicate a potential upside of 16.52% from the company's current price.

A number of other brokerages also recently commented on DVA. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $265.00 target price on shares of DaVita in a research note on Wednesday, August 5th. Zacks Research downgraded DaVita from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. Raymond James Financial set a $220.00 target price on DaVita in a research note on Friday, August 7th. TD Cowen upped their price target on DaVita from $220.00 to $228.00 and gave the company a "buy" rating in a report on Monday. Finally, UBS Group reiterated a "buy" rating and issued a $287.00 price target on shares of DaVita in a research note on Monday. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $235.86.

DaVita Trading Down 1.1%

DVA traded down $2.13 on Monday, hitting $185.37. 881,900 shares of the company were exchanged, compared to its average volume of 895,771. The firm has a 50-day moving average price of $181.36 and a two-hundred day moving average price of $176.50. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49. The company has a market cap of $11.66 billion, a price-to-earnings ratio of 13.65, a price-to-earnings-growth ratio of 0.48 and a beta of 0.87.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.57 by $0.25. The business had revenue of $3.58 billion during the quarter, compared to analysts' expectations of $3.52 billion. DaVita had a negative return on equity of 225.93% and a net margin of 6.49%. The business's quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.51 EPS. Equities analysts expect that DaVita will post 14.74 EPS for the current year.

Institutional Trading of DaVita

Several institutional investors and hedge funds have recently bought and sold shares of DVA. Berkshire Hathaway Inc purchased a new position in DaVita during the 2nd quarter worth $6,425,269,000. BlackRock Inc. purchased a new stake in shares of DaVita in the second quarter valued at about $547,520,000. Dimensional Fund Advisors LP raised its holdings in shares of DaVita by 5.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company's stock valued at $176,037,000 after buying an additional 56,336 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of DaVita during the second quarter worth about $145,057,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of DaVita by 81.2% during the first quarter. Bank of New York Mellon Corp now owns 457,493 shares of the company's stock worth $70,312,000 after buying an additional 204,984 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

About DaVita

DaVita Inc NYSE: DVA is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.